Drug intelligence / Profile preview

DW4421-N1

Development stage: Unknown
Lead developer: Daewon Pharm
Modality: Small Molecules
Administration: Oral

Overview

**DW4421-N1** is a sponsor-designated intervention label used in Daewon's Phase 1 drug-drug-interaction study of padoprazan (DW4421) with three nonsteroidal anti-inflammatory drugs in healthy adults. Public trial materials identify DW4421-N1 only as one of the NSAID comparator interventions; they do not disclose its underlying active ingredient, pharmacologic target, formulation, manufacturer, or independent development program. It should not be conflated with DW4421, which is padoprazan.

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on DW4421-N1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW4421-N1.

Explore the full profile